Breakthrough CBD Delivery Method Improves Epilepsy, MS Therapies

Cannabis derived compounds are showing their versatility once again, as researchers at the University of South Australia (UniSA) have developed a cannabidiol (CBD) formulation that could drastically improve treatment outcomes for individuals living with the following debilitating conditions:

• Epilepsy: a neurological disorder marked by recurring seizures, which CBD has been proven to reduce in severity and frequency.
• Multiple sclerosis (MS): a chronic condition where the immune system attacks the protective covering of nerves, disrupting communication between the brain and body.  Here, CBD has been found to help with resulting pain, muscle spasticity, and sleep quality.

This new formulation was introduced through a recently published study¹ detailing a phospholipid-based CBD complex that significantly enhances the compound’s water solubility, permeability, and overall bioavailability – an innovation poised to further unlock CBD’s full therapeutic potential.

The team from UniSA emphasized the real-world impact of this breakthrough, stating:

“Improved bioavailability means that lower doses can achieve the same therapeutic effect, potentially reducing side effects and making treatment more cost effective” – UniSA Phd canadidate Thabata Muta

CBD’s Bioavailability Problem—And the Breakthrough Solution

Despite its well-documented benefits in seizure control and inflammation, CBD is often held back from its full potential due to poor water solubility, which results in limited gastrointestinal absorption.  Oral forms typically have a bioavailability of just 6%, meaning the majority of the dose never reaches systemic circulation.  Looking to address this issue, the UniSA research team formulated a CBD-phospholipid complex (CBD-PLC).

Upon developing their solution, the new complex was put through extensive testing that included everything from dynamic light scattering, FTIR, ¹H-NMR, and Caco-2 permeability assays.  The results were very promising, with the complex having effectively,

• Reduced CBD’s lipophilicity (log Po/w dropped from 7.54 to 0.13)
• Enhanced permeability and intestinal uptake
• Increased oral release rates from 0% (pure CBD) to 67.1% at 3 hours
• Maintained structural integrity and efficacy for up to 12 months

Simply put, early results indicate that improved bioavailability achieved by this delivery system holds immense promise, particularly for chronic neurological disorders where consistent, effective dosing is critical.  Combined with advancements being seen with nanotechnologies, cannabis appears poised to play an increasing role in modern medicine.

A New Frontier for MS and Epilepsy Treatment

Epilepsy and MS patients, in particular, often struggle with inadequate symptom relief using standard medications.  This is often due to associated side effects, complex symptoms, and even drug resistance in 1/3 of patients suffering from seizures.

CBD, however, has already proven effective in managing certain forms of epilepsy, including Lennox–Gastaut and Dravet syndromes, and is already approved through FDA-approved offerings. However, accessibility and efficacy have been hampered by shortcomings in the delivery system.  This new formulation addresses these issues and improves therapeutic outcomes without increasing dosage in the process – potentially minimizing side effects and improving adherence.

Cannabis: A Versatile Therapeutic Tool

Notably, the study by the UniSA is just one of the many examples of cannabis’s potential that has been shared in recent months.  A growing body of evidence underscores how various cannabinoids benefit a wide range of health issues:

• Pain Management: As explored in How Medical Cannabis Helps Chronic Pain from Hypermobility, cannabis can reduce pain and inflammation associated with joint hypermobility syndromes—often where traditional painkillers fail.
• Weight Management: THCV Weight Loss Study reveals how tetrahydrocannabivarin (THCV), a non-psychoactive cannabinoid, can help reduce body fat and improve metabolic markers, offering a novel approach to obesity treatment.
• Improved Sleep: Cannabis, CBN, and Sleep discusses how cannabinol (CBN) may promote better sleep quality, particularly when combined with CBD and other cannabinoids.

Clearly, the growing list of research highlights cannabis as more than a niche wellness supplement – it is rapidly becoming a multipurpose tool with widespread benefits to one’s health and wellness.

Final Thoughts

Overall, the new phospholipid-based CBD formulation offers more than just better bioavailability – it represents the latest step forward in making cannabinoid-based therapies more effective, stable, and accessible.  Whether for MS, epilepsy, pain, sleep, or metabolic health, cannabis-based solutions are showing remarkable versatility.

As new delivery systems and cannabinoid profiles are refined, patients around the world stand to benefit from a new generation of evidence-based, targeted cannabis therapies.

Studies Referenced:

^{1. Muta, T., Khetan, R., Song, Y., & Garg, S. (2025). Optimising cannabidiol delivery: Improving water solubility and permeability through phospholipid complexation. International Journal of Molecular Sciences, 26(6), 2647. https://doi.org/10.3390/ijms26062647}